Literature DB >> 11950553

Increased serum interleukin-8 and interleukin-10 in schizophrenic patients resistant to treatment with neuroleptics and the stimulatory effects of clozapine on serum leukemia inhibitory factor receptor.

Michael Maes1, Luisella Bocchio Chiavetto, Stefano Bignotti, Giani-Jean Battisa Tura, Rosaria Pioli, Francesco Boin, Gunter Kenis, Eugene Bosmans, Raf de Jongh, Carlo A Altamura.   

Abstract

There is now evidence that schizophrenia may be accompanied by an activation of the monocytic and T-helper-2 (Th-2) arms of cell-mediated immunity (CMI) and by various alterations in the Th-1 arm of CMI. There is also evidence that repeated administration of typical and atypical antipsychotics may result in negative immunomodulatory effects. This study was carried out to examine (1) the serum concentrations of interleukin-8 (IL-8), IL-10, the soluble CD8 (sCD8) and the leukemia inhibitory factor receptor (LIF-R) in nonresponders to treatment with typical neuroleptics as compared with normal volunteers and responders to treatment; and (2) the effects of atypical antipsychotics on the above immune variables. The latter were determined in 17 nonresponders to treatment with neuroleptics and in seven normal volunteers and 14 schizophrenic patients who had a good response to treatment with antipsychotic agents. The nonresponders had repeated measurements of the immune variables before, and 2 and 4 months after treatment with clozapine or risperidone. Serum IL-8 and IL-10 were significantly higher in schizophrenic patients than in normal controls. The serum concentrations of the sCD8 were significantly increased 2 months, but not 4 months, after starting treatment with atypical antipsychotics. Serum LIF-R concentrations were significantly increased 2 and 4 months after starting treatment with atypical antipsychotics. It is concluded that: (1) schizophrenia is characterized by an activation of both pro-inflammatory and anti-inflammatory aspects of cell-mediated immunity; (2) prolonged treatment with atypical antipsychotics may increase the anti-inflammatory capacity of the serum in schizophrenic patients by increasing serum LIF-R concentrations; and (3) short-term treatment with clozapine may induce signs of immune activation which disappear upon prolonged treatment.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11950553     DOI: 10.1016/s0920-9964(00)00094-3

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  38 in total

Review 1.  Schizophrenia and autism: both shared and disorder-specific pathogenesis via perinatal inflammation?

Authors:  Urs Meyer; Joram Feldon; Olaf Dammann
Journal:  Pediatr Res       Date:  2011-05       Impact factor: 3.756

Review 2.  COX-2 inhibitors as adjunctive therapy in schizophrenia: rationale for use and evidence to date.

Authors:  Michael Riedel; Martin Strassnig; Markus J Schwarz; Norbert Müller
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

3.  A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression.

Authors:  D R Goldsmith; M H Rapaport; B J Miller
Journal:  Mol Psychiatry       Date:  2016-02-23       Impact factor: 15.992

Review 4.  Research in people with psychosis risk syndrome: a review of the current evidence and future directions.

Authors:  Christoph U Correll; Marta Hauser; Andrea M Auther; Barbara A Cornblatt
Journal:  J Child Psychol Psychiatry       Date:  2010-02-26       Impact factor: 8.982

5.  Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects.

Authors:  Brian J Miller; Peter Buckley; Wesley Seabolt; Andrew Mellor; Brian Kirkpatrick
Journal:  Biol Psychiatry       Date:  2011-06-08       Impact factor: 13.382

6.  Smoking and Serum Lipid Profiles in Schizophrenia.

Authors:  Hui-Mei An; Yun-Long Tan; Shu-Ping Tan; Jing Shi; Zhi-Ren Wang; Fu-De Yang; Xu-Feng Huang; Jair C Soars; Thomas R Kosten; Xiang-Yang Zhang
Journal:  Neurosci Bull       Date:  2016-03-28       Impact factor: 5.203

Review 7.  Factors associated with response to clozapine in schizophrenia: a review.

Authors:  Takefumi Suzuki; Hiroyuki Uchida; Koichiro Watanabe; Haruo Kashima
Journal:  Psychopharmacol Bull       Date:  2011

8.  Chronic phencyclidine induces inflammatory responses and activates GSK3β in mice.

Authors:  Shenghua Zhu; Hongxing Wang; Ruoyang Shi; Ruiguo Zhang; Junhui Wang; Lynda Kong; Yingxia Sun; Jue He; Jiming Kong; Jun-Feng Wang; Xin-Min Li
Journal:  Neurochem Res       Date:  2014-10-01       Impact factor: 3.996

Review 9.  Molecular mechanisms underlying synergistic effects of SSRI-antipsychotic augmentation in treatment of negative symptoms in schizophrenia.

Authors:  Yael Chertkow; Orly Weinreb; Moussa B H Youdim; Henry Silver
Journal:  J Neural Transm (Vienna)       Date:  2009-07-04       Impact factor: 3.575

10.  Abnormalities in chemokine levels in schizophrenia and their clinical correlates.

Authors:  Suzi Hong; Ellen E Lee; Averria Sirkin Martin; Benchawanna Soontornniyomkij; Virawudh Soontornniyomkij; Cristian L Achim; Chase Reuter; Michael R Irwin; Lisa T Eyler; Dilip V Jeste
Journal:  Schizophr Res       Date:  2016-09-17       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.